rx semaglutide Compound 1 receptor agonist). Sublingual Semaglutide and weight loss

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status

If you have a specific health condition, labs on file, or are currently on medications, let us know at intake so your provider can confirm the right protocol for your session

Eat more sulfur-rich foods like garlic and cruciferous vegetables and make sure you get enough selenium

& Blaschke, G

Glutathione as a skin-lightening agent: Facts, myths, evidence and controversies

Oxid Med Cell Longev 2022;2022:1821780